Bone Marrow Transplantation (BONE MARROW TRANSPL)

Publications in this journal

• Article: Duration of first remission, hematopoietic cell transplantation-specific comorbidity index and patient age predict survival of patients with AML transplanted in second CR.

  Michelis FV, Atenafu EG, Gupta V, Kim DD, Kuruvilla J, Lambie A, Lipton JH, Loach D, Messner HA
  Bone Marrow Transplantation 05/2013;
• Article: IFN-gamma microsatellite polymorphism as a risk factor of post alloHSCTcomplications revisited – Polish Donor-Recipient Matching Study Group

  A. Lange, B. Wysoczanska, A. Mizia, M. Polak, A. Gronkowska, J. Nowak, S. Kyrcz-Krzemien, M. Markiewicz, M. Dzierzak-Mietla, W. Olchowy, [......], ANDRZEJ HELLMANN, A. Kucharska, J. Kowalczyk, K. Drabko, K. Warzocha, A. Tomaszewska, R. Mika-Witkowska, A. Dlugokecka, J. Gozdzik, A. Mordel
  Bone Marrow Transplantation 04/2012; 47(supl. 1):163.
• Article: Donor cell MDS in a 12-year-old girl 3 years after allogeneic haematopoietic stem cell transplantation for MDS, both with a t(3;3)(q21;q26) aberration

  R. Leguit, H. van den Berg, A. Buijs, C. Mellink, M. Bierings
  Bone Marrow Transplantation 06/2011;
• Article: Retrospective analysis of treatment-related toxicities and outcome in high-risk Ewing sarcoma patients receiving PO or IV busulfan-based high-dose chemotherapy with autologous stem cell transplantation

  A. Ranft, S. Jabar, U. Dirksen, K. Ehlert, J. Boos, P. Bader, R. Ladenstein, H. Jürgens
  Bone Marrow Transplantation 04/2011; 46(1):S381-S381.
• Article: Hematopoietic Stem Cell Biology

  C W E So
  Bone Marrow Transplantation 02/2011; 46(3):474-474.
• Article: CRMCC

  Daisuke Asai
  Bone Marrow Transplantation 01/2011;
• Article: Plerixafor with and without chemotherapy in poor mobilizers: results from the German compassionate use program

  K H|[uuml]|bel, M M Fresen, H Salwender, N Basara, R Beier, S Theurich, M Christopeit, C Bogner, O Galm, R Hartwig, [......], M Ebinger, N Frickhofen, B Hertenstein, M Kiehl, S Liebler, M von Lilienfeld-Toal, E Weidmann, C Weigelt, F Lange, N Kr|[ouml]|ger
  [show abstract] [hide abstract]
  ABSTRACT: The CXCR4-inhibitor plerixafor mobilizes hematopoietic stem cells amplifying the effects of granulocyte-CSF (G-CSF). Before approval plerixafor was used in a compassionate use program (CUP) for patients who failed a previous mobilization. In the German CUP 60 patients from 23 centers (median age 56.5 years (2–75)) were given 240 μg/kg plerixafor SC 9–11 h before apheresis. A total of 78.3% (47/60) received G-CSF for 4 days before plerixafor administration; 76.6% of those (36/47) yielded at least 2.0 × 106 CD34+ cells/μL. The median cell yield was 3.35 × 106 CD34+ cells/kg (0–29.53). Nine patients received plerixafor alone or with G-CSF for less than 4 days mobilizing a median of 3.30 × 106 CD34+ cells/kg (1.6–5.6). There was no significant difference between G-CSF application for 4 days and for a shorter period of time (P=0.157). A total of 47 patients received plerixafor plus G-CSF combined with chemotherapy yielding a median of 3.28 × 106 CD34+ cells/kg (0–24.79). In all, 40 of 60 patients (66.7%) proceeded to transplantation, and achieved a timely and stable engraftment. Side effects were rare and manageable. In conclusion, mobilization with plerixafor in poor mobilizers is safe and results in a sufficient stem cell harvest in the majority of patients.Keywords: plerixafor; poor mobilizers; stem cell mobilization
  Bone Marrow Transplantation 10/2010; 46(8):1045-1052.
• Article: Clinical efficacy and safety of primary antifungal prophylaxis with posaconazole vs itraconazole in allogeneic blood and marrow transplantation

  I S|[aacute]|nchez-Ortega, B Pati|[ntilde]|o, M Arnan, T Peralta, R Parody, C Gudiol, M Encuentra, A Fern|[aacute]|ndez de Sevilla, R F Duarte
  [show abstract] [hide abstract]
  ABSTRACT: Posaconazole has been recently approved for primary antifungal prophylaxis in patients with prolonged neutropenia after AML induction chemotherapy and patients with GVHD. We now present the first experience of the efficacy and safety of posaconazole during the early phase of post-allogeneic BMT (n=33; from June 2007), in comparison with itraconazole primary prophylaxis (n=16; up to May 2007). More patients receiving posaconazole were T-cell depleted (P=0.003). Groups were otherwise comparable in terms of age, sex, disease, neutrophil engraftment, incidence of GVHD, use of unrelated donors and type of conditioning. Safety data as well as the incidence of fever (84%) and persistent fever (27%) during the 100-day treatment period were comparable for both antifungal agents. Patients receiving posaconazole had a lower cumulative incidence of proven or probable invasive fungal disease, as defined by the European Organization for Research and Treatment of Cancer criteria (0 vs 12%; P=0.04), which associated with a higher probability of fungal-free survival (91 vs 56%; P=0.003) and an improved probability of OS (91 vs 63%; P=0.011) compared with patients receiving itraconazole. Our single-centre experience suggests that antifungal prophylaxis with posaconazole may lead to a better outcome than itraconazole for patients in the early high-risk neutropenic period after allogeneic BMT.Keywords: antifungal prophylaxis; allogeneic transplantation; itraconazole; posaconazole
  Bone Marrow Transplantation 08/2010; 46(5):733-739.
• Article: Pediatric hematopoietic SCT in Mexico: recent activity and main problems

  L Rodr|[iacute]|guez-Romo, O Gonz|[aacute]|lez-Llano, C Mancias-Guerra, J C Jaime-P|[eacute]|rez, A G|[oacute]|mez-Pe|[ntilde]|a, G Ru|[iacute]|z-Arguelles, G Ru|[iacute]|z-Delgado, A Olaya, A del Campo, I Montero, O Gonz|[aacute]|lez-Ramella, A Sandoval, G Gonz|[aacute]|lez, T Pompa, C Galindo, D G|[oacute]|mez-Almaguer
  Bone Marrow Transplantation 06/2010; 46(4):607-609.
• Article: Comparative analysis of BU and CY versus CY and TBI in full intensity unrelated marrow donor transplantation for AML, CML and myelodysplasia

  J P Uberti, M-A Agovi, S Tarima, M Haagenson, S Gandham, C Anasetti, K S Baker, B J Bolwell, M Bornhauser, K W Chan, E Copelan, S M Davies, J Finke, G A Hale, C Kollman, P L McCarthy, V Ratanatharathorn, O Ringd|[eacute]|n, D J Weisdorf, J D Rizzo
  [show abstract] [hide abstract]
  ABSTRACT: We retrospectively compared clinical outcomes in 1593 T-replete unrelated donor (URD) marrow transplant recipients with AML, MDS and CML who received myeloablative conditioning regimens of either BU and CY (BuCy), standard-dose Cy/TBI (1000–1260 cGy) or high-dose Cy/TBI (1320–1500 cGy). Subjects were drawn from patients transplanted between 1991 and 1999 facilitated by the National Marrow Donor Program. Patients who received high-dose Cy/TBI regimens were slightly younger, more likely to receive a mismatched transplant and to have intermediate or advanced disease compared with patients in the BuCy or standard-dose TBI group. Neutrophil recovery was significantly higher in the standard-dose CY/TBI group compared with the high-dose Cy/TBI or BuCy group. Patients who received the high-dose Cy/TBI regimen had an increased risk of developing grades III–IV aGVHD when compared with the control group who received BuCy (P=0.011). OS, disease-free survival (DFS), TRM and relapse were not significantly different between any of the regimens. We conclude that BuCy, standard-dose and high-dose Cy/TBI regimens have equivalent efficacy profiles for OS, DFS, TRM and relapse risk in patients undergoing T-replete URD marrow transplantation for AML, CML and MDS.Keywords: unrelated donor transplantation; TBI conditioning regimens; BU
  Bone Marrow Transplantation 04/2010; 46(1):34-43.
• Article: Plerixafor plus granulocyte CSF can mobilize hematopoietic stem cells from multiple myeloma and lymphoma patients failing previous mobilization attempts: EU compassionate use data

  R F Duarte, B E Shaw, P Mar|[iacute]|n, P Kottaridis, M Ortiz, C Morante, J Delgado, J Gayoso, R Goterriz, C Mart|[iacute]|nez-Chamorro, J J Mateos-Maz|[oacute]|n, C Ram|[iacute]|rez, J de la Rubia, H Achtereekte, P J Gandhi, K W Douglas, N H Russell
  [show abstract] [hide abstract]
  ABSTRACT: Plerixafor was recently approved by the US Food and Drug Administration (FDA) and the European Medicines Evaluation Agency (EMEA) to enhance stem cell mobilization for autologous transplant in patients with lymphoma and multiple myeloma. In this study, we present the first European compassionate use experience in mobilization failures, patients who are hardest to remobilize but were not included in registration trials. A total of 56 consecutive patients from 15 centers in Spain and the United Kingdom were included: age 60 (33–69) years; 29 men (32 with myeloma and 24 with lymphoma); 2 lines of previous chemotherapy (1–10); 73 previously failed mobilization attempts with G-CSF (28), chemotherapy plus G-CSF (43) or G-CSF plus SCF(2). Overall, 71% of patients reached 10 CD34+ cells per μL with plerixafor on day 5 after a 7.6-fold expansion from day 4. A total of 42 patients (75%) collected 2 × 106, average 3.0±1.7 (0.4–10.6) CD34+ cells per kg with plerixafor plus G-CSF. There were no severe drug-related adverse events. In all, 35 patients (63%) underwent transplant, receiving an average of 3.1±1.2 (1.9–7.7) × 106 CD34+ cells per kg. All patients engrafted neutrophils (day 12; 13.4±0.8; 8–30) and platelets (day 15; 18.5±2.4; 8–33). In our experience, plerixafor offers an effective alternative to collect sufficient CD34+ cells for autologous SCT from patients who fail conventional mobilization methods, with good tolerance and a high success rate.Keywords: plerixafor; AMD3100; PBSC; autologous transplantation; mobilization
  Bone Marrow Transplantation 03/2010; 46(1):52-58.
• Article: Hematopoietic SCT activity in Asia: a report from the Asia-Pacific Blood and Marrow Transplantation Group

  A Yoshimi, R Suzuki, Y Atsuta, M Iida, D-P Lu, W Tong, A Ghavamzadeh, K Alimoghaddam, A K W Lie, R Liang, [......], L Haipeng, P-L Tan, W Y K Hwang, T-J Chiou, P-M Chen, T Van Binh, N N Minh, C-K Min, T J Hwang, Y Kodera
  [show abstract] [hide abstract]
  ABSTRACT: The hematopoietic SCT (HSCT) activity in nine Asian countries/regions was surveyed to overview the current situation. Data of 58 113 HSCTs (allogeneic: 63% vs autologous: 37%) performed between 1986 and 2006 by 432 transplant teams were collected. The number of HSCTs has been increasing in the past two decades in most countries/regions. The increase in allogeneic HSCTs is greater than in autologous HSCTs. The proportion of unrelated donors among allogeneic HSCTs in 2006 varied widely from <1% (Iran and Vietnam) to 62% (Japan). The use of each stem cell source, that is, BM, PBSC, cord blood and others (including co-infusion of BM and PBSC), also varied widely (36, 58, 0.1 and 6% in HSCT from related donors, respectively, and 53, 11, 35 and 1% in HSCT from unrelated donors, respectively). HSCTs have been continuously increasing for all indications except for chronic myelogenous leukemia and solid tumors. Hemoglobinopathy is a common indication among non-malignant diseases in many Asian countries/regions except for China, Japan and Korea. This survey clearly shows the recent progress of HSCTs in Asia and also some differences in donor and stem cell selection and disease application among countries/regions.Keywords: hematopoietic SCT; registry; Asia
  Bone Marrow Transplantation 02/2010; 45(12):1682-1691.
• Article: Engraftment syndrome after auto-SCT: analysis of diagnostic criteria and risk factors in a large series from a single center

  E Carreras, F Fern|[aacute]|ndez-Avil|[eacute]|s, L Silva, M Guerrero, C Fern|[aacute]|ndez de Larrea, C Mart|[iacute]|nez, L Rosi|[ntilde]|ol, M Lozano, P Mar|[iacute]|n, M Rovira
  [show abstract] [hide abstract]
  ABSTRACT: Engraftment syndrome (ES) is increasingly observed in patients who receive auto-SCT. To investigate this fact, validate the clinical criteria for ES diagnosis and analyze the risk factors for this complication, we reviewed 328 consecutive peripheral blood auto-SCT performed during the past 7 years. A total of 43 patients presented with clinical or biological data suggestive of ES. Of the total, 41 (95%) and 22 (51%) could be diagnosed with ES using the Maiolino criteria (MC) and the Spitzer criteria (SC), respectively. The SC were less sensitive as they do not consider some relevant clinical data and limit the observation time after engraftment. All ES cases had high C-reactive protein (CRP) values not observed in the remaining patients at engraftment (median±s.d.: 17.5±7.3 vs 2.4±3.4 mg per 100 ml; P=0.0001). Multivariate analysis showed a higher risk of ES in SCT performed in recent years (relative risk (RR) 2.3, 95% confidence interval (CI 1.0–4.7), female patients (RR 2.5, 95% CI 1.2–5.2), and absence of intensive chemotherapy before SCT (RR 8.8, 95% CI 3.3–20.5). All patients except one improved after treatment with corticosteroids. The MC seem to be the best tool to establish a diagnosis of ES. In doubtful cases, the diagnosis could be confirmed by evaluating CRP. Auto-SCT in patients not receiving previous chemotherapy could explain the increasing incidence of ES in the past years.Keywords: engraftment syndrome; early complications after SCT; C-reactive protein; auto-SCT
  Bone Marrow Transplantation 01/2010; 45(9):1417-1422.
• Article: Characterization of hemopoietic engraftment kinetics and development of secondary cytopenia in acute myeloid leukemia post autologous stem cell transplantation and its correlation with survival outcome

  Samuel B, Tan Daryl, Heng, Kee Khiang, Lee, Jing Jing, Loh, Su Ming Yvonne, Hwang, Ying Khee William, Koh, Boon Chai Mickey, Goh, Yeow Tee, Linn, Yeh Ching
  Bone Marrow Transplantation 08/2009;
• Article: Haematopoietic stem cell transplantation in clinical practice

  N Novitzky
  Bone Marrow Transplantation 07/2009; 44(4):271-271.
• Article: Influence of mannose-binding lectin genotypes and serostatus in allo-SCT: analysis of 131 recipients and donors

  O W Neth, U Bacher, P Das, T Zabelina, H Kabisch, N Kroeger, F Ayuk, M Lioznov, O Waschke, B Fehse, R Thi|[eacute]|baut, R M Haston, N Klein, A R Zander
  [show abstract] [hide abstract]
  ABSTRACT: Mannan-binding lectin (MBL) deficiency is determined by MBL gene polymorphisms and is associated with an increased infection risk. To clarify the role of MBL in Allo-SCT, 131 recipients–donors were analysed. MBL genotypes were determined by PCR and heteroduplex analyses, MBL serum levels by ELISA, and MBL oligomers by western blotting. MBL levels <400 ng/ml were associated with increased susceptibility to fungal pneumonia (7/12 vs 35/111; P=0.04, adjusted P=0.002), HSV/VZV (7/12 vs 26/111; P=0.03), CMV reactivation and acute GVHD. Donor genotypes had no influence. Pre-SCT MBL levels corresponded to recipients’ genotypes (P<0.001), changed significantly post-SCT, but were not influenced by donors’ genotypes. MBL oligomer profiles were similar pre-/post-SCT. Cultured CD34+ cells were found not to synthesise MBL. In conclusion, low MBL levels pre-transplant predisposed patients to sepsis, fungal and viral infection. Donors’ MBL genotypes did not influence infection rates. Prospective studies should clarify the importance of MBL as a prelude for MBL replacement after SCT.Keywords: mannan-binding lectin protein, MBL variants, sepsis, infection, Allo-SCT
  Bone Marrow Transplantation 05/2009; 45(1):13-19.